Trial Profile
A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Mar 2024 Status changed from active, no longer recruiting to discontinued due to low accrual.
- 23 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2019 Planned number of patients changed from 62 to 4.